NeuroAiD at World Congress of Neurology
Moleacâs flagship product, NeuroAiD, will be presented at the 23rd Word Congress of Neurology...
NeuroAiD presentations at European Stroke Conference
NeuroAiD, Moleacâs main product, will be presented at the 26th European Stroke Conference on 24th...
NeuroAiD presentations at European Stroke Organisation Conference
NeuroAiD, Moleacâs main product, will be presented at the 3rd European Stroke Organisation...
Launch of NeuroAiD in Nigeria
Helping patients reconnect with their lives remain our focus. This February, NeuroAiD will be...
Moleac awarded prize from Creative France â recognising the success of French entrepreneurs in Singapore
âEntrepreneurâ is a French invention for risk takers committed to innovate, and Moleac is a...
Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiDâ˘) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery â Extension Study
Cerebrovasc Dis 2017; 43:36-42 Published by S. Karger AG, Basel This analysis from the CHIMES-E...
Moleacâs Flagship Product NeuroAiD Named Asia Pacific Neurological Disorders New Product Innovation of the Year At the Frost & Sullivan Best Practices Awards
NeuroAiDâ˘Â has been named New Product Innovation of the Year by Frost & Sullivan. This award...
NeuroAiD⢠has shown persistent long-term benefits after an initial 3-month treatment following stroke onset
Moleac is pleased to announce the release of the CHIMES-E study results published online in the...
Chinese Herbal Medicine May Have Delayed Benefit in Stroke
VIENNA, Austria â Long-term follow-up of a trial investigating a Chinese herbal supplement in...
